| Ytd | -61.19% | |
| 1y | -43.60% |
| Open | 4.92 | Prev Close | 4.88 | Low | 4.42 | High | 4.92 | Mkt Cap | 14.71M |
| Vol | 57.70K | Avg Vol | 116.37K | EPS | -11.84 | P/E | N/A | Forward P/E | -1.30 |
| Beta | 1.20 | Short Ratio | 6.61 | Inst. Own | 59.68% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 03-03 | 50-d Avg | 5.32 | 200-d Avg | 8.33 | 1yr Est | 8.00 |
PASG News
Gainers Atlantic International (NASDAQ:ATLN) shares increased by 41.0% to $1.1 during Thursday'
Gainers Adicet Bio (NASDAQ:ACET) stock moved upwards by 22.9% to $10.14 during Thursday's pre-m
Gainers American Shared Hospital (AMEX:AMS) stock rose 14.2% to $1.61 during Wednesday's after-
Passage Bio, Inc. (Nasdaq: PASG) ("Passage Bio") and Remix Therapeutics, Inc. ("Remix
Chardan Capital analyst Janani Sundararajan downgrades Passage Bio (NASDAQ:PASG) from Buy to Neut
Wall Street analysts changed outlook for top names, including downgrading Mohawk Industries and Pass
Oppenheimer analyst Jay Olson maintains Passage Bio (NASDAQ:PASG) with a Outperform and lowers th
Wedbush analyst Yun Zhong downgrades Passage Bio (NASDAQ:PASG) from Outperform to Neutral and low
US stocks down at midday, Dow down 0.2%, NASDAQ down 0.52%. Energy up 1.1%, consumer discretionary d
US stocks mixed, energy shares climb. Cleveland-Cliffs falls 6% after reporting Q1 results. Enveric
Regulatory & Program UpdateThe Company has completed a Type C meeting with the FDA to seek guida
Corporate UpdateThe Company has initiated a review of strategic alternatives to maximize shareholder
PBFT02 administration resulted in improvements in two disease progression biomarkers, as compared to
Oppenheimer analyst Jay Olson initiates coverage on Passage Bio (NASDAQ:PASG) with a Outperform r
Canaccord Genuity analyst Whitney Ijem maintains Passage Bio (NASDAQ:PASG) with a Buy and lowers
Passage Bio (NASDAQ:PASG) reported quarterly losses of $(4.09) per share which missed the analyst co
Chardan Capital analyst Geulah Livshits maintains Passage Bio (NASDAQ:PASG) with a Buy and raises
Passage Bio (NASDAQ:PASG) reported quarterly losses of $(2.44) per share which beat the analyst cons
Canaccord Genuity analyst Whitney Ijem maintains Passage Bio (NASDAQ:PASG) with a Buy and lowers
Guggenheim analyst Debjit Chattopadhyay maintains Passage Bio (NASDAQ:PASG) with a Buy and lowers
Wedbush analyst Yun Zhong maintains Passage Bio (NASDAQ:PASG) with a Outperform and raises the pr
Passage Bio (NASDAQ:PASG) reported quarterly losses of $(2.96) per share which missed the analyst co
Chardan Capital analyst Geulah Livshits maintains Passage Bio (NASDAQ:PASG) with a Buy and mainta
PBFT02 continued to demonstrate robust, durable elevation in CSF PGRN levels and improvement in plas
Chardan Capital analyst Geulah Livshits maintains Passage Bio (NASDAQ:PASG) with a Buy and lowers
Updated interim data from FTD-GRN patients treated with Dose 1 PBFT02:BiomarkersDose 1 of PBFT02 tre
Wedbush analyst Yun Zhong assumes Passage Bio (NASDAQ:PASG) with a Outperform rating and announce
Chardan Capital analyst Geulah Livshits maintains Passage Bio (NASDAQ:PASG) with a Buy and mainta
Canaccord Genuity analyst Whitney Ijem maintains Passage Bio (NASDAQ:PASG) with a Buy and maintai
Passage Bio (NASDAQ:PASG) reported quarterly losses of $(0.31) per share which missed the analyst co